EL.En. (ELN) H1 2024 earnings summary

Executive summary

• H1 2024 revenues declined 9.5% year-over-year to €312.9 million, mainly due to industrial sector weakness, while EBIT fell 12% to €34.2 million, maintaining a 10.9% margin.

• Net income rose 5.9% year-over-year to €27.3 million, supported by improved margins and a €5 million one-time gain from the remeasurement of a financial liability linked to a failed IPO.

• The medical sector was resilient, limiting its revenue decline to 1.7%, while the industrial sector saw a sharp 19.9% drop, especially in the cutting segment.

• International expansion, product innovation, and favorable sales mix, especially in anti-aging and urology, supported performance in key segments.

• International market conditions, high interest rates, and delayed investment incentives in Italy and China weighed on demand, particularly in the industrial segment.

Financial highlights

• Gross margin improved to 41.2% from 38% year-over-year, aided by a €1.9 million insurance reimbursement for flood damages.

• EBITDA was €41.4 million, down 9.3% year-over-year, with EBITDA margin stable at 13.2%.

• Net financial position increased to €68.6 million, up from €54.6 million at 2023 year-end, supported by operational cash flow, non-recurring inflows, and partial disposal of liquidity investments.

• Net working capital rose to €234.79 million, with the ratio to sales increasing to 37.5% from 33.3% year-over-year, reflecting seasonal and inventory factors.

• Dividend of €0.20 per share paid in May 2024, totaling €16–17 million.

Outlook and guidance

• Full-year revenue is not expected to fully recover the H1 shortfall, but EBIT is forecast to exceed 2023 due to a favorable sales mix and higher-margin international sales.

• Medical sector revenues are expected to surpass 2023 in the second half, underpinning the annual guidance.

• Management remains optimistic about medium-term growth, driven by R&D, innovation, and internationalization.